«

»

Humira biosimilars earn spot on OptumRx’s formulary

OptrumRx, UnitedHealth's pharmacy benefit manager, will keep AbbVie's best-selling rheumatoid arthritis drug Humira on its formulary in 2023 alongside three competing biosimilar versions set to debut next year, Bloomberg reported Nov. 15.

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive